Cozad Asset Management Inc. Buys Shares of 2,616 Edwards Lifesciences Co. (NYSE:EW)

Cozad Asset Management Inc. bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,616 shares of the medical research company’s stock, valued at approximately $250,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock valued at $3,992,709,000 after purchasing an additional 729,984 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Edwards Lifesciences by 9.5% during the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock valued at $1,813,089,000 after purchasing an additional 1,644,869 shares during the last quarter. Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 20.1% during the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after purchasing an additional 3,048,274 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 2.4% during the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after purchasing an additional 393,109 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $648,540,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total transaction of $622,050.00. Following the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,636,549.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Scott B. Ullem sold 7,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total transaction of $622,050.00. Following the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,636,549.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $14,639,824.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,099 shares of company stock valued at $7,003,553. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Down 0.1 %

Shares of Edwards Lifesciences stock opened at $87.19 on Thursday. The stock has a market cap of $52.54 billion, a P/E ratio of 37.64, a P/E/G ratio of 3.21 and a beta of 1.11. The stock’s 50 day simple moving average is $89.14 and its 200-day simple moving average is $86.68. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group assumed coverage on Edwards Lifesciences in a research note on Thursday, May 30th. They issued a “buy” rating and a $107.00 target price for the company. Morgan Stanley raised their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Royal Bank of Canada raised their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Truist Financial raised their target price on Edwards Lifesciences from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Friday, April 26th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $96.76.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.